Anthropic, the company behind the Claude AI models, is launching its own drug development program aimed at neglected diseases — the kind the pharmaceutical industry has long treated as too unprofitable to pursue, according to The Decoder.
The move is notable because it puts an AI company directly into the business of discovering treatments, rather than simply selling tools to the drugmakers who do that work. Neglected diseases tend to affect poorer populations and offer little commercial payoff, which is why they are often left underfunded despite significant human cost.
The promise driving this kind of effort is speed and better odds. Novartis CEO Vas Narasimhan believes AI could cut drug development time from roughly twelve years down to seven or eight, and double the industry's success rate from 8 percent to 16 percent, The Decoder reports. In an industry where most candidate drugs fail and each attempt costs enormous sums, even modest gains in those numbers could reshape what is worth trying.
The report does not specify which diseases Anthropic will target first, how the program will be funded, or when treatments might reach patients. Narasimhan's figures also reflect the potential of AI across the industry broadly, not a guarantee tied to Anthropic's specific effort.
Still, the direction is significant. If AI can meaningfully lower the time and cost of finding new medicines, treatments that were once dismissed as economically hopeless could become viable — and that is why a program like this matters well beyond the tech world.